drugset / Trial / NCT06141460
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related Macular Degeneration
Timeline
- Start
- 2023-12-12
- Primary completion
- 2026-04-15
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RRG001 | Gene therapy (AAV / viral vector) | — | Other |